Medical Week Daily

Medical news today: Friday, November 13, 2026

WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect

Get tomorrow's issue in your inbox.

  1. 01

    WHO's Global Tuberculosis Report 2026 shows progress but persistent diagnostic and treatment gaps

    Source: World Health Organization

    WHO's 2026 Global Tuberculosis Report, released on November 12, estimates that 10.6 million people developed TB and 1.1 million died from it in 2025. Domestic TB funding rose 14% to US$5.6 billion between 2024 and 2025, partly offsetting a similar-scale decline in international financing, but an estimated 2.2 million people with TB were undiagnosed or unreported. WHO also reports that only 42% of people estimated to have rifampicin-resistant TB received treatment in 2025.

    Why it mattersThe report shows that declining mortality has not closed major gaps in diagnosis, rapid testing and drug-resistant TB treatment. For public-health and PV teams, the funding mix and low treatment coverage are important implementation signals; the report is surveillance evidence, not a new therapeutic recommendation. More on Infectious disease →

  2. 02

    WHO reports India and Bangladesh have declared national bans on paraquat

    Source: World Health Organization

    WHO reported on November 12 that India and Bangladesh declared national bans on paraquat in September 2026. The agency links the regulatory action to prevention of fatal pesticide ingestion and protection of agricultural workers and brain health, noting that acute pesticide ingestion is implicated in a substantial share of suicides worldwide. WHO describes lives saved as an expected benefit; the release does not report measured post-ban outcomes.

    Why it mattersRestricting access to highly toxic pesticides is a population-level means-safety intervention with implications for poisoning surveillance, occupational health and regulatory implementation. The anticipated public-health benefit should not be presented as an observed effect before post-ban data are available. More on Approvals & regulatory →

  3. 03

    MHRA issues a Class 4 notification for a carton-strength typo on enalapril/hydrochlorothiazide tablets

    Source: Medicines and Healthcare products Regulatory Agency

    The MHRA published a Class 4 medicines defect notification on November 12 after the marketing-authorisation holder reported that the front of cartons for enalapril maleate/hydrochlorothiazide 20 mg/12.5 mg tablets incorrectly prints the hydrochlorothiazide strength as '12. mg'. Other carton faces, the patient leaflet and blister foil show 12.5 mg. Four batches are listed; the MHRA says tablet quality is unaffected and the product should continue to be dispensed.

    Why it mattersThis is a low-risk labelling-defect notification, not a recall or a finding of compromised tablet quality. It is relevant to dispensing checks and medication reconciliation: the MHRA asks healthcare professionals to note the notice and reassure patients that the tablet strength remains 12.5 mg. More on Drug & device safety →

  4. 04

    Phase 3 trial reports improved survival with izalontamab brengitecan in previously treated esophageal cancer

    Source: JAMA

    JAMA published results from the open-label, randomized PANKU-Esophagus01 phase 3 trial in 497 patients with recurrent or metastatic esophageal squamous cell carcinoma after first-line PD-1/PD-L1 inhibitor plus platinum-containing chemotherapy. Izalontamab brengitecan improved median progression-free survival to 4.17 versus 1.97 months (hazard ratio 0.50) and interim median overall survival to 9.79 versus 7.20 months (hazard ratio 0.63) versus physician-selected chemotherapy. Grade 3 or higher treatment-related adverse events occurred in 85.1% versus 59.3%; the trial was conducted across 80 hospitals in China.

    Why it mattersThe findings are promising for a heavily pretreated population, but the absolute median survival gains are measured in months and severe toxicity was more frequent. This publication is clinical evidence, not a marketing authorization; regulatory review and longer-term benefit-risk assessment remain important. More on Approvals & regulatory →

  5. 05

    Phase 2 CAMORAL trial finds longer event-free survival with perioperative camrelizumab plus chemotherapy

    Source: JAMA Oncology

    The multicentre, open-label CAMORAL phase 2 randomized trial, conducted at four hospitals in China, included 125 adults with resectable stage III to IVB head and neck squamous cell carcinoma. Two-year event-free survival was 77.8% with perioperative camrelizumab plus chemotherapy versus 46.1% with standard surgery-based treatment (hazard ratio 0.34; 95% CI 0.17–0.68). Grade 3 or higher treatment-emergent adverse events were more common in the perioperative arm (79.4% versus 56.5%).

    Why it mattersThe results add randomized evidence for a perioperative immunotherapy approach in resectable head and neck cancer, but the small phase 2 sample and higher rate of severe adverse events mean the regimen should not be treated as established standard care. Confirmatory trials and careful safety assessment remain necessary. More on Approvals & regulatory →

  6. 06

    Biomarker-guided antibiotics did not demonstrate noninferiority in very preterm infants

    Source: JAMA Network Open

    A multicentre randomized trial across 17 Italian neonatal intensive care units enrolled 283 very preterm infants. Survival without major morbidity was 53% with procalcitonin/presepsin-guided antibiotic initiation and 55% with universal treatment; the prespecified noninferiority criterion was not met. Biomarker guidance reduced the proportion receiving antibiotics (58% versus 98%), but no early-onset sepsis cases occurred, limiting assessment of diagnostic sensitivity.

    Why it mattersThe study suggests biomarker-guided initiation may reduce antibiotic exposure, but it did not establish that the approach is a safe substitute for universal treatment in this high-risk population. The absence of confirmed early-onset sepsis and the wide confidence interval limit conclusions; routine adoption as an alternative is not supported by these data. More on Approvals & regulatory →

New here? How to read this digest
Each story links to its original source. "Why it matters" explains what it means for you in plain language. This is news, not medical advice: talk to your doctor about your own care. Browse all topics or the archive.

More recent digests

Free daily email

The day's approvals, safety signals and trials, in five minutes.

Join the list with just your email. You can also follow the RSS feed.

Free, one field, no spam. We only use your address to send Medical Week Daily and never sell it. Ask to be removed any time via the contact page. See the privacy note.

For information and education only. Not medical advice. Medical Week Daily summarizes published health news in plain language for general readers. It does not replace advice from your doctor, product labeling or regulatory documents. Always consult a qualified healthcare professional about your own care, and check the original source. Full medical disclaimer